Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, developed by Takeda. It acts as a proteasome inhibitor and has orphan drug status in the US.

CAS：1072833-77-2
中文别名：阿西咗眯;埃沙佐米;B-[(1R)-1-[[2-[(2,5-二氯苯甲酰基)氨基]乙酰基]氨基]-3-甲基丁基]硼酸;阿西佐米;
英文别名：MLN 2238;Ninlaro;{(1R)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic acid;[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid;(R)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid;B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid;
分子式：C14H19BCl2N2O4
分子量：361.029
精确质量：360.081
Psa：98.66
Logp：2.4678

MDL号：MFCD18251438

外观与性状：固体
密度：1.306 g/cm3
可溶性：溶于DMSO，不溶于水